Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This review suggests that while finasteride for male pattern hair loss was previously considered safe, there is now evidence associating 5-α reductase inhibitors with significant sexual and reproductive side effects.

This review discusses the prevalence and etiologies of sexual dysfunction in young men, highlighting the increased recognition of organic causes alongside psychosomatic factors, and reports no new clinical results.

This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

This preliminary study suggests that finasteride may be an effective treatment option for patients with hidradenitis suppurativa, as six out of seven participants showed significant improvement.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

This article provides a critical overview of recent discoveries in the genetics and molecular processes involved in androgenetic alopecia, focusing on its polygenic basis and DHT dependency, but reports no new clinical results.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.